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HIGHLIGHTS
1. Patients with non-severe aortic stenosis have elevated echocardiographic markers of
left ventricular filling pressure.
2. Echocardiographic markers of increased left ventricular filling pressure are independently associated with increased mortality in patients with non-severe AS.
3. These markers may be useful to identify high-risk subgroups that may benefit from
closer surveillance and potentially earlier intervention.
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ABSTRACT

Background: Echocardiographic measures of elevated left ventricular filling pressures are associated with an adverse prognosis. The aim of this study was to determine the relationship
between acute (ratio of early transmitral flow to mitral annular velocities; E/e’) and chronic
(indexed left atrial volume; LAVI) markers of left ventricular filling pressure (LVFP) and mortality in patients with non-severe aortic stenosis (AS), within the National Echo Database of
Australia cohort. We hypothesised that they would reflect the early haemodynamic consequences of AS and be associated with increased mortality in this setting.
Methods:

The first record for patients 18 years or over showing hemodynamically signif-

icant but non-severe (mild or moderate) AS (mean pressure gradient ≥10 to <40mmHg and
AVA>1cm2) was analysed. Baseline demographics and echocardiographic variables were
compared to patients without AS (mean pressure gradient <10mmHg). Mortality linkage data
were available for all patients.
Results: Of 78,886 patients with aortic valve mean pressure gradient <40mmHg and
AVA>1cm2, 13,768 (17%) were identified with non-severe AS (aortic valve mean pressure
gradient 10-40mmHg), of which 57% were male (mean age 73 ±13.4 years) with a median
follow-up of 3.4 years (interquartile range: 1.7-6.1 years). In unadjusted models, non-severe
AS and a LAVI>34ml/m2 [Hazard Ratio (HR)=2.29 (95% CI 2.03-2.58)], an E/e’>14
[HR=2.27 (95% CI 2.08-2.49)], a left ventricular ejection fraction (LVEF) <50% [HR 2.82
(95% CI 2.50-3.19)], and a tricuspid regurgitation (TR) peak velocity>280cm/s [HR=2.54
(95% CI 2.30-2.80)] were associated with increased mortality hazard. The effect remained independent when combined in a multi-variable model.
Conclusions: Indices of elevated LVFP are independently associated with death in non-severe
AS. Risk stratification models incorporating these variables may identify patients at risk of
complications, warranting closer surveillance and possibly earlier intervention.

Keywords:

Echocardiography, observational, aortic stenosis, left ventricular filling pres-

sure, mortality.
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ABREVIATIONS
Aortic stenosis:

AS

National Echocardiography Database of Australia:

NEDA

Left ventricular filling pressure:

LVFP

Aortic valve replacement:

AVR

Ratio of early transmitral flow to mitral annular velocity:

E/e’

Indexed left atrial volume:

LAVI

Left atrial:

LA

National Death Index:

NDI

International Classification of Diseases:

ICD

Cardiovascular disease:

CVD

Aortic valve:

AV

Aortic valve area:

AVA

Tricuspid regurgitation:

TR

Left ventricular ejection fraction:

LVEF

Interquartile range:

IQR

Standard deviation:

SD

Confidence interval:

CI

Left ventricular:

LV

Hazard ratio:

HR
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INTRODUCTION
Aortic stenosis (AS) is an increasingly prevalent condition, affecting 4-5% of those aged over
sixty-five years, and associated with a high mortality.(1) Recent data from the National Echocardiography Database of Australia (NEDA) demonstrated poor long-term survival in patients
with moderate AS, challenging traditional definitions of severity and timing of invasive intervention in this population.(2) While patients with moderate AS do not currently meet criteria
for valve intervention, some studies suggest that a significant proportion will progress to severe
stenosis within the current recommended window for echocardiographic follow-up.(3-4) Furthermore, there is mounting evidence that patients with chronically elevated left ventricular
filling pressures (LVFP) may not re-model following aortic valve replacement (AVR).(5) Identifying patients in the pre-severe range at higher mortality risk, who may benefit from closer
surveillance and potentially from earlier intervention, may therefore be important.
Data for echocardiographic predictors of survival in AS are currently predominately
limited to indices reflecting systolic function and stenosis severity.(6) However, diastolic parameters, reflecting acute and chronic elevation in LVFP, confer a worse prognosis in many
conditions (7-12) and are frequently abnormal in patients with AS as a consequence of increased myocardial stiffness. An elevated ratio of early mitral inflow E-wave peak velocity to
peak early relaxation mitral annular tissue Doppler velocity (E/e’ ratio) remains the most robust
echocardiographic surrogate of acutely elevated LVFP and is a reliable marker of LVFP in
patients with AS.(13) Indexed left atrial volume (LAVI), which reflects medium to long-term
LVFP, is also required to accurately diagnose and quantify diastolic dysfunction.(14-16) We
anticipate that these parameters would reflect the haemodynamic consequences of AS and be
useful predictors of outcome in this setting.
Our aim was to determine the relationship between markers of increased LVFP (measured primarily by LAVI and the mitral E/e’ ratio) and mortality in non-severe (mild and moderate) AS using the extensive NEDA database. We hypothesised that these markers would be
independently associated with mortality in this cohort.
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METHODS
Study Setting and Design:
The NEDA dataset was first described in the original NEDA report (17) and more recently in
an analysis of mortality in patients with moderate AS.(2) NEDA is a very large observational
registry that captures individual echocardiographic data (combined with basic demographic
profiling) on a retrospective and prospective basis from participating centres throughout Australia. At the time of study census, a total of 12 centres had contributed >500,000 investigations
(approximately 20 million measurements) from approximately 350,000 individuals undergoing
echocardiography. NEDA is also registered with the publicly accessible Australian New Zealand Clinical Trials Registry (ACTRN12617001387314). Ethical approval has been obtained
from all relevant Human Research Ethics Committees.
Study Data:
All echocardiographic measurement and report data contained in the echocardiographic database of a participating centre is collected (study period April 11, 2000 to June 13, 2017). Each
database is remotely transferred into a central database using a “vendor-agnostic”, automated
data extraction process that transfers every measurement for each echocardiogram obtained in
an entire echocardiography database into a standard NEDA data format. Precise definitions for
each echocardiography variable are applied. Variables with the same name as the NEDA standard are automatically matched. Variables with different names are manually matched with the
NEDA standard by the Principal Investigator. Duplicate measurements with different naming
conventions are combined. Units are transformed to the single NEDA standard, and repeated
measures for the same variable are converted to a single variable according to the NEDA Study
Protocol. Additional text recognition software captures free text, clinical comments, and conclusions. A continuously updated NEDA Data Dictionary is maintained through a Master
NEDA Database that forms the basis for all subsequent analyses. To address the pre-specified
hypotheses, individual NEDA data were linked to Australia’s National Death Index (NDI).(18)
With enhanced probability matching, this linkage provided reliable data on the survival status
and primary cause of death of individuals up to the study census date of October 20, 2017. If
an individual had died, the listed causes of death were categorized according to International
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Classification of Diseases-10th Revision (ICD-10) coding. Subsequently, consistent with previous reports of this type (19), all ICD-10 (Australian Modification) chapter codes in the range
of 100 to 199 were considered a cardiovascular disease (CVD) related death.
Study Cohort:
NEDA data as of October 20, 2017 were used to identify the following: 1) men and women
≥18 years of age; and 2) at least one echocardiographic investigation. We included the first
echocardiogram per patient showing hemodynamically significant but non-severe AS; defined
by aortic valve (AV) mean pressure gradient greater than or equal to 10mmHg and less than
40mmHg and aortic valve area (AVA) greater than 1cm2, where present. Where patients had
more than one echocardiogram and with none of these indicating AS, the first echo was included. Patients with aortic valve replacements were identified through text extraction and excluded from the analysis. We identified separately a group without hemodynamically significant AS (AV mean pressure gradient <10mmHg, also with AVA>1cm2) as a comparator for
baseline echocardiographic characteristics only.
Study Measures:
Echocardiographic markers reflecting elevated LVFP included; 1) Left atrial (LA) volume indexed to body surface area (ml/m2) and 2) E/e’ ratio (unitless). Important prognostic indicators
reflecting both pulmonary hypertension, represented by maximum tricuspid regurgitation (TR)
velocity (cm/s), and left heart disease, represented by left ventricular ejection fraction (LVEF),
were incorporated in the analysis.(17)
LAVI and E/e’ ratio was recorded from raw data and, where absent, populated from text comment fields. LVEF was measured using primarily the percentage chosen by the reporting physician, followed by the Simpson’s biplane, four and two chamber values respectively and followed lastly by Teichholz method if none of the aforementioned variables were populated.
Echocardiographic variables were represented as continuous variables and also dichotomised
using cut-off ranges identified by the American Society of Echocardiography 2016 Recommendations for the Evaluation of Diastolic Function, i.e. LAVI >34ml/m2, average E/e’>14
and TR velocity> 280cm/s.(16) The normal cut off for LVEF was defined as 50% or higher.
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Statistical analysis:
No formal calculations of study power were performed given the large number of cases, fatal
events, and patient-years of follow-up. Data were analysed using STATA version 15
(StataCorp, College Station, Texas, USA) and SPSS version 23.0 (SPSS Inc., Chicago, Illinois). Normally distributed continuous data are presented as means (standard deviation [SD])
and skewed data as median (IQR). Categorical data are expressed as frequencies and proportions (with 95% confidence intervals (CI) as appropriate). The “non-severe AS” and “no AS”
groups were compared with respect to demographics and echocardiographic variables to establish baseline differences between the populations, particularly with respect to patterns of abnormal LVFP. Between-group comparisons were made using Student’s two sided t test or chisquare tests. The remainder of the analysis focussed on the non-severe AS cohort. The association between echocardiographic variables and all-cause mortality was initially investigated
using Cox proportional hazard models. The proportional hazards assumption was assessed by
visual examination of smoothed plots of Schoenfeld residuals versus time. Suspected violations
were confirmed by testing interactions of all echocardiographic variables with time in a Cox
regression model (time varying coefficient model). Univariate analysis was performed on dichotomised forms of the echocardiographic variables. All statistically significant variables
were included in the multivariable time varying coefficient models, along with age and sex.
Interactions between echocardiographic markers were tested. Only patients with all multivariate variables populated were included in the final multivariate analysis. Variations in the HRs
over time were plotted for each variable, incorporating the effect of sex and age (fixed at the
sample average) on the risk of death. A test of the Cox proportional hazards assumption for the
included variables revealed non-proportionality for all variables except LAVI, indicating a
time-varying effect. This was likely contributed to by the prolonged duration of follow-up.
Kaplan Meier survival curves were used to demonstrate mortality differences between subgroups. Statistical significance was accepted as a two-sided p value of <0.05.

RESULTS
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There were 78,886 patients 18 years or older with aortic valve mean pressure gradient
<40mmHg, AVA>1cm2 and no history of AVR. Of these, there were 13,768 patients (17%)
identified with AV mean gradient ≥10-40mmHg; 57% were male with mean age 74 years and
median follow up of 3.4 years [Q1-Q3 =1.7-6.1, Interquartile range (IQR) =4.4]. In total, 4,848
fatal events were recorded in the non-severe AS group (35% of the non-severe AS cohort). The
final cohort included in the multivariate model comprised patients with populated data for all
variables of interest and consisted of 3,777 patients.
Baseline demographic and echocardiographic characteristics of interest are summarized in Table 1. Patients in the non-severe AS cohort were older with a higher proportion of males, as
compared to those without AS. Unadjusted baseline echocardiographic markers of LVFP were
higher in the non-severe AS cohort, as compared to those with no AS; LAVI 38.4 ml/m2 vs
32.4 ml/m2 (p<0.001), E/e’ 13.2 vs 12.0 (p<0.001). There was a statistical but not clinically
significant difference in LVEF between groups (62.5% in non-severe AS vs 60.0% in those
with no AS, p<0.001). Furthermore, patients with non-severe AS demonstrated elevated pulmonary pressure, reflected by increased peak TR velocities (277cm/s vs 256 cm/s, p<0.001).
Non-severe AS was associated with an unadjusted two-fold risk of death compared to no AS:
median survival 8.7 years vs 14.8 years, respectively (HR 2.02, 95% CI 1.95–2.10, p<0.001).
The excess mortality in the non-severe AS group largely reflected the older population. After
adjusting for age and sex, the remaining risk of mortality in non-severe AS patients was 7%
(HR 1.07, 95% CI 1.03–1.10, p<0.001). Adjusting for the absence of sinus rhythm had minimal
effect on the observed hazard (HR = 1.06, 95% CI 1.02-1.10, p = 0.002).
Amongst patients with non-severe AS, all echocardiographic parameters were associated with
increased mortality in a univariable model (Table 2). The proportional hazards assumption was
violated in either univariate or multivariable analysis for all echocardiographic variables, indicating varying hazard over time. For some parameters, the violation was minor and likely
detected due to the power of the sample. However, the effect in LVEF <50% was more substantial and over time. When incorporated in a time-varying coefficients multivariable model
and adjusted for age and sex, all variables remained independently associated with death over
time. No significant interactions between echocardiographic markers were detected. Table 2
displays the HRs for each variable in the multivariable analysis at baseline as well as the change
over time per year where relevant. For patients with LVEF<50%, the risk of death was esti-
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mated to be more than double the risk of death in those with LVEF≥50% at the time of echocardiography (HR=2.38, 95%CI: 1.79-3.17, p<0.001) but this risk decreases by 13% per year
over the follow up period (HR=0.87, 95%CI: 0.81-0.94, p<0.001). The change in mortality
risk over time from the baseline echocardiogram is displayed in Figure 1 and was generated
using estimates from the time varying coefficients multivariable model, assuming the average
age of the sample. The pattern over time in males appears slightly different to females but this
is due to the increased risk of mortality associated with being male (HR=1.36, 95%CI:1.211.53, p<0.001), not a variation in the change over time in the echocardiographic parameters
between genders. LAVI demonstrated a stable risk of death over the follow-up period whilst
the risk associated with elevated E/e’ increased over time (E/e’>14 became significant by one
year follow-up and conferred 5% increased risk per year thereafter). Conversely, the prognostic
impact of LVEF<50% and TR peak velocity<280cm/s decreased with time. The risk associated
with elevated E/e’ surpassed that of having a reduced LVEF after approximately four years
follow-up.
Table 3 demonstrates the incremental effect on mortality with one or more markers of elevated
LVFP and/or reduced LVEF, adjusted for age and sex. Patients who exhibited LAVI>34ml/m2,
E/E’>14, TR velocity>280ms and LVEF<50% had almost three-fold risk of mortality (HR
2.88, 95% CI 2.10-3.96, p<0.0001) compared to those with values below each of these thresholds. The unadjusted prognostic impact of markers of elevated LVFP in the presence of both
normal and low LVEF is demonstrated in Kaplan Meier curves in Figure 2 (LAVI>34) and
Figure 3 (E/E’>14).

DISCUSSION
The results from analysis of this large multi-centre echocardiography database support the hypothesis that markers of acute and chronic elevated LVFP, namely LAVI and E/e’, are associated with increased all-cause mortality in the non-severe AS population independent of age,
sex, LVEF and pulmonary hypertension.

We observed the presence of higher LVFP in patients with non-severe AS (AV mean gradient
≥10 to <40mmHg) compared to those without hemodynamically significant AS (AV mean
gradient <10mmHg). We postulate two mechanisms for this. Firstly, it seems likely that this
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reflects, at least in part, the haemodynamic consequences of AS, which results in early left
ventricular remodelling and diastolic dysfunction. Secondly, elevated LVFP likely represents
the final common pathway of multiple factors which increase myocardial stiffness and determine outcome, including blood pressure, atrial fibrillation and age. While this relationship is
not specific to AS, it is clinically useful to know that patients with elevated LVFP are at increased risk within this group; particularly as we know that even if this abnormality is not
exclusively, or even primarily, related to the AS it would be expected that AS will exacerbate
it over time.

While the haemodynamic sequelae of elevated LVFP in patients with severe AS are widely
appreciated, the significance in patients with non-severe AS has been previously under-recognised. Our findings are consistent with former studies in other settings which demonstrate the
prognostic importance of elevated LVFP and markers of diastolic dysfunction. (7-12) Recent
data from the NEDA cohort demonstrated an association between markers of diastolic dysfunction (including LAVI and septal E/e’) and death in patients with AS using an artificial
intelligence model. (20) A second publication showed that impaired valvular haemodynamics
in the setting of AVR was associated with the same trajectory as in native AS. (21) Within the
non-severe AS cohort, other studies outside the NEDA population have shown markers of myocardial dysfunction to be associated with poor outcomes. Levy-Neuman and colleges demonstrated the relationship between peak and post exercise basal longitudinal strain and increased
rate of future cardiovascular events in asymptomatic patients with moderate AS. (22) Other
parameters including pressure recovery–adjusted aortic valve area and the ratio of aortic valve
acceleration to ejection time have also been found to be useful in risk-stratifying patients with
moderate to severe aortic stenosis. (23-24) There are, however, few previous data addressing
the prognostic value of E/e’, LAVI and other echocardiographic indices of elevated LVFP in
the non-severe AS cohort over time. Biner and colleagues described E/e’ as the single most
predictive clinical and echo Doppler marker of overall prognosis amongst a small cohort
(n=125) of patients with un-operated severe AS. (25) Rusinaru demonstrated an association
between increased LA volume and mortality in patients with at least mild severity AS, although
again in a small population. (26)
Although LAVI and E/e’ are routinely measured in echocardiographic assessment of diastolic
dysfunction, they remain under-represented in guidelines for echocardiogram-based risk stratifications of AS, which focus on stenosis severity and LVEF in guiding intervention. (1) We
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therefore propose that the incorporation of LAVI and particularly E/e’ in risk stratification
models for patients with non-severe AS, in addition to traditional markers of stenosis severity
and left ventricular function, may be useful in guiding future clinical decision making; though
currently there are no data supporting valve replacement in non-severe AS. This is, however,
an issue that is currently being explored in the Transcatheter Aortic Valve Replacement to
UNLOAD the left ventricle in patients with advanced heart failure (TAVR UNLOAD) trial
(NCT02661451) which is testing the hypothesis that transcatheter aortic valve replacement
plus optimal medical therapy improves the outcome of patients with moderate AS and heart
failure with reduced LVEF when compared to optimal medical therapy alone.
LIMITATIONS
There are a few limitations to this study. NEDA cohort typically comprises individuals being
investigated for possible or pre-existing cardiovascular disease. NEDA does not (yet) capture
important clinical details pivotal to outcomes relevant to AS and conditions such as coronary
artery disease, hypertension and diabetes. We did identify patients with “non-sinus” rhythm
by the presence of a documented E wave without a documented A wave. However, on an adjusted basis, the absence of sinus rhythm did not significantly influence the threshold for increased mortality and had had little impact on the model overall (data not shown). Furthermore,
the echocardiographic variables contained within the NEDA database rely on the reports of
individual laboratories and hence contain a significant proportion of missing values which may
have introduced bias. Finally, these data were largely derived from specialist centers or clinics
in Australia and care should be exercised when extrapolating these results to the rest of the
world. Since this study, NEDA has continued to extend the number of contributing centers to
improve applicability of these data to the entire population.

CONCLUSION
These data describe the prognostic implications of markers of LVFP in a very large cohort of
adults over a prolonged period. Markers of raised LVFP were shown to be independently associated with mortality in this population. These easily measured and routinely available echocardiographic parameters might therefore be useful to identify high-risk subgroups that may
benefit from closer surveillance and potentially earlier intervention. This, however, is an area
requiring further prospective evaluation.
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Echocardiographic predictors of outcomes in adults with aortic stenosis. Heart
2016;102:934–42.

7. Hillis GS, Møller JE, Pellikka PA, Gersh BJ, Wright RS, Ommen SR et al. Noninvasive
estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after
acute myocardial infarction. J Am Coll Cardiol 2004;43(3):360-7.

15
8. Wang M, Yip G, Yu C, Zhang Q, Zhang Y, Tse D et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic
function. J Am Coll Cardiol 2005;45(2):272-7.
9. Møller J, Hillis G, Oh J et al. Left Atrial Volume; a powerful predictor of survival after
acute myocardial infarction. Circ. J. 2003;107:2207-12.
10. Rossi A, Temporelli P, Quintana M. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data
(MeRGE Heart Failure). Eur J Heart Fail 2009;11:929-36.

11. Playford D, Strange G, Celermajer D et al. Diastolic dysfunction and mortality in 436 360
men and women: the National Echo Database Australia (NEDA). Eur Heart J Cardiovasc Imaging 2020;00:1-11.
12. Playford D, Stewart S, Celermajer D et al. Poor survival with impaired valvular hemodynamics after aortic valve replacement: The National Echo Database Australia study. J Am
Soc Echocardiogr 2020;33(9):1077-86.
13. Bruch C, Stypmann J, Grude M, Gradaus R, Breithardt G, Wichter T. Tissue Doppler imaging in patients with moderate to severe aortic valve stenosis: clinical usefulness and diagnostic accuracy. Am Heart J 2004;148:696-702.
14. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM et al. Clinical
utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788–94.

16
15. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP et al.
Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical
practice. J Am Soc Echocardiogr 2009;22(1):1-23.
16. Nageuh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography:
an update from the American Society of Echocardiography and the European Association of
Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-31.

17. Strange G, Celermajer DS, Marwick T, Prior D, Ilton M, Codde J et al. The National
Echocardiography Database Australia (NEDA): rationale and methodology. Am Heart J
2018;204:186–9.

18. Magliano D, Liew D, Pater H, Kirby A, Hunt D, Simes J et al. Accuracy of the Australian
National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study.
Aust N Z J Public Health 2003;27:649–53.

19. Strange G, Stewart S, Celermajer DS, Prior D, Scalia GM, Marwick TH et al. Threshold
of pulmonary hypertension associated with increased mortality. J Am Coll Cardiol 2019;
73:2660–72.

20. Playford D, Bordin E, Mohamad R, Stewart S, Strange G. Enhanced Diagnosis of Severe
Aortic Stenosis Using Artificial Intelligence: A Proof-of-Concept Study of 530,871 Echocardiograms. JACC Cardiovasc Imaging 2020;13(4):1087-90.

17
21. Playford D, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, et al. Poor survival
with impaired valvular hemodynamics after aortic valve replacement: The National Echo Database Australia Study. J Am Soc Echocardiogr 2020;33:1077-86.

22. Levy-Neuman S, Meledin V, Gendelman G, Goland S, Zilberman L, Edri O et al. The association between longitudinal strain at rest and stress and outcome in asymptomatic patients
with moderate and severe aortic stenosis. J Am Soc Echocardiogr 2019;32:722-9.

23. Ringle Griguer A, Tribouilloy C, Truffier A, Vincentelli A, Bohbot Y, Maréchaux S.
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Hazard Ratios over time derived from a time varying coefficient Cox regression

model in males and females with non-severe AS, stratified by LAVI cut-off of 34ml/m2, E/e’
cut-off of 14, LVEF cut-off of 50% and TR peak velocity cut-off of 280cm/s. LAVI demonstrates non-proportionality with fixed risk over time, whilst hazard associated with E/e’ increases over the follow-up period. LAVI = Left atrial volume indexed, E/e’ = Ratio of early
mitral inflow E-wave peak velocity to peak early relaxation mitral annular tissue Doppler velocity, LVEF = Left ventricular ejection fraction, TR = tricuspid regurgitation.
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Kaplan Meier 10-year survival in patients with non-severe AS with and without

reduced LVEF, as stratified by LAVI cut-off of 34ml/m2. This graph compares survival curves
of patients with different categories of LAVI and LVEF. Values per line represent the number
and percentage deceased at 10-years as a proportion of the initial number per category. Abbreviations as per Figure 1.
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Kaplan Meier 10-year survival in patients with non-severe AS with and without

reduced LVEF as stratified by E/e’ cut-off of 14. This graph compares survival curves of patients with different categories of E/e’ and LVEF. Values per line represent the number and
percentage deceased at 10-years as a proportion of the initial number per category. Abbreviations as per Figure 1.
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TABLE 1. Baseline characteristics of study cohort (n=78,886)
Characteristic

No AS (n=65,118)

Non-Severe AS

22
P Value

(n=13,768)
Demographic Profile
Male, %
Age at echo, years (%)

50.8

57.2

<0.001

60.8 (17.8)

73.7 (13.4)

<0.001

28.4 (6.8)

28.6 (6.5)

<0.001

14.8 (14.6-.)*

8.7 (8.5-8.9)

<0.001

4.4 (1.8)

16.0 (6.2)

<0.001

60.0 ± 12.2

62.5 ± 11.4

<0.001

(n=41,542)

(n=9,939)

32.4 ± 15.3

38.4 ± 16.3

(n=22,995)

(n=7,968)

12.0 ± 5.2

13.2 ± 5.9

(n=22360)

(n=6,560)

255.9 ± 51.3

277.3 ± 49.2

(n=33,266)

(n=9,200)

Anthropometrics
Body Mass Index, kg/m2

Median time to death, years (CI)

Mean AV gradient, mmHg (SD)
Echocardiographic characteristics
LVEF (%)

LAVI (ml/m2)

E/e’ (unitless)

TR peak velocity (cm/s)

<0.001

<0.001

<0.001

Values are mean ±SD, or median (interquartile range *upper bound of the CI does not drop
below 0.5). Available data for echocardiographic characteristics are displayed in parentheses.
AS = aortic stenosis; CI = confidence interval, AV = aortic valve; LVEF = left ventricular

23
ejection fraction. LAVI = left atrial volume, indexed, E/e’ = ratio of early transmitral flow (E)
to mitral annular (e’) velocity, HR = hazard ratio, TR = tricuspid regurgitation.

Ali TABLE 2. Variables associated with increased all-cause mortality in non-severe AS (n = 13,768)v
24
Characteristic

Alive

Dead

Univariate

P Value

(n as indicated)
1.06#

Age at Echo

4977/8920 2903/4848
(55.8%)

LAVI >34ml/m2
(at baseline)

(59.9%)

2265/5021 1865/2947
(45.1%)

(63.3%)

LAVI >34ml/m2 * time

1.11#

<0.001

(variation per year)
520/6361

640/3578

2.82

(at baseline)

(8.2%)

(17.9%)

(2.50-3.19)

LVEF <50% * time

0.91

(variation per year)

(0.88-0.94)

(at baseline)

1796/5528 1883/3672
(32.5%)

(51.3%)

2.54

0.94

* time (variation per year)

(0.92-0.96)

(at baseline)
E/e’ >14 * time
(variation per year)

1.36#

<0.001

(1.21-1.53)
<0.001

1.18#

0.006

(1.05-1.34)
0.002

N/A

<0.001

2.38

<0.001

(1.79-3.17)
<0.001

0.87

<0.001

(0.81-0.94)
<0.001

(2.31-2.80)

TR peak velocity >280cm/s

E/e’ >14

<0.001

(0.94-0.99)

LVEF <50%

TR peak velocity >280cm/s

<0.001

(2.03-2.58)
0.96

1.08#
(1.07-1.08)

(1.05-1.18)
2.29

P Value

(n=3777)

(1.06-1.07)
Male

Multivariate

1.65

<0.001

(1.35-2.01)
<0.001

0.96

0.042

(0.92-1.00)

1229/4597

838/1963

2.27#

(26.3%)

(42.7%)

(2.08-2.49)

(0.96-1.43)

N/A

1.05

<0.001

1.17

(1.01-1.09)

Values are expressed as a proportions and percentages of available records. Other abbreviations
are as per Table 1. *multivariable HR is based on a final sample of 3777 patients in the proportional hazards model with time varying coefficients at baseline (time of echocardiogram),

0.12

0.023

25
adjusted for age, sex and all other echocardiographic variables tested. #Constant hazard across
all follow-up years. Additional footnotes as per table 2.

TABLE 3. Mortality risk by cumulative echocardiographic markers of systolic and diastolic function in
non-severe aortic stenosis

Number of Abnormal

Proportion, n (%)

Hazard Ratio (95% CI)

P Value

0

1270 (33.6)

Reference

1

1264 (33.5)

1.29 (1.11-1.52)

<0.001

2

780 (20.7)

1.69 (1.43-2.00)

<0.001

3

396 (10.5)

2.67 (2.21-3.21)

<0.001

4

68 (1.8)

2.88 (2.10-3.96)

<0.001

Echo Features*
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*Echo features = LAVI>34ml/m2, E/E>14, TR peak velocity>280cm/s and LVEF<50%. Hazard ratio is age and sex-adjusted (95% CI) - abbreviations are as per Table 1.

